Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00421538
Status:
COMPLETED
Last Update Posted:
2018-05-04
First Post:
2007-01-11
Brief Title:
Randomized Controlled Trial of Anticoagulation vs Placebo for a First Symptomatic Isolated Distal Deep-vein Thrombosis IDDVT
Sponsor:
University Hospital Geneva
Organization:
University Hospital Geneva
Study Overview
Official Title:
Contention Alone Versus Anticoagulation for Symptomatic Calf Vein Thrombosis Diagnosed by Ultrasonography
Status:
COMPLETED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CACTUS-PTS
Brief Summary:
CACTUS-PTS is a randomized placebo-controlled double-blind study which aims primarily to determine the effectiveness of a 6 week course of therapeutic-dose LMWH nadroparine injections vs placebo in patients with a first symptomatic isolated distal calf deep-vein thrombosis IDDVT as measured by rate of proximal DVT and symptomatic PE at 6 weeks Additionally the study aims to determine if the 6 week course of treatment with therapeutic-dose LMWH nadroparine injections compared to placebo decreases the frequency of post-thrombotic syndrome PTS at 1 year
Detailed Description:
The CACTUS-PTS study will compare anticoagulant treatment for 6 weeks versus placebo in acute symptomatic distal DVT Patients will be randomized to receive either a six-week period of LMWH at therapeutic dosage or a six-week period of placebo All patients will be treated with elastic compression stockings and followed-up with a standardized ultrasonography protocol Strict ultrasonographic diagnostic criteria for distal DVT have been defined Control compression ultrasonography will be performed between days 3 and 7 and at six weeks after inclusion The primary outcome will be a composite of the proportion of patients with extension of the thrombus to the proximal veins detected by the programmed ultrasound examinations or by an ultrasound performed because of recurrent symptoms or symptomatic PE in both arms of the study during the 6-weeks study period Patients with such an outcome will be anticoagulated as currently admitted in presence of a proximal DVT Secondary outcomes will be the individual components of the composite endpoint distal DVT extension to proximal veins symptomatic PE major bleeding serious adverse events and death reported at 6 weeks and 90 days To answer the research question of the PTS add-on study patients will self-assess and be assessed for PTS by a clinician using the Villalta scale 1 year following their enrolment into the trial In addition patients will complete a Quality of Life QOL questionnaire The QOL questionnaire will be comprised of both the VEINES-QOL and SF-36 The primary outcome is the rate of PTS with secondary outcomes of QOL scores and PTS severity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CACTUS-PTS Trial | None | None | None |